


IPW



**UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of : May 13, 2004  
LISZIEWICZ, et al. : Atty Docket No. RGT 7033  
Serial No. 10/757,343 : Group 1633  
Filed: January 14, 2004 : Examiner: Unknown

**For: DNA Composition and Uses  
Thereof**

Mail Stop Non-Fee Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


**Letter Re Information Disclosure<sup>1</sup>**

Enclosed is an Information Disclosure Citation that, to the best of the applicant's knowledge, is being filed before the mail date of the first Office Action.


Copies of all the non-patent references are included, *except* for the Vincenzi reference on page 3, which was unavailable at the time of filing. That reference and the reference immediately after it (Zhou) are cited for the same proposition in the text of the application.

The Commissioner is authorized to charge any additional fees due, or credit any excess paid, to Deposit Account No. 500855. Two copies of this sheet are enclosed.

Respectfully Submitted,

  
Valerie E. Looper  
Registration No. 33,007

The Law Offices of  
Valerie E. Looper  
11726 Lightfall Court  
Columbia, Maryland 21244  
(410)-715-5771  
(410) 715-5773 (fax)

<sup>1</sup> This paper is being forwarded to the Commissioner for Patents, Mail Stop Non-Fee Amendment, Box 1450 Alexandria, VA 22313-1450 by first class mail with sufficient postage on May 13, 2004 by Valerie E. Looper, signed 

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
RGT 7033

In Re Application Of: Lisiewicz, et al.

Serial No.  
10/757,343

Filing Date  
14 Jan 2004

Examiner

Group Art Unit  
1633

Title:

Address to:

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**37 CFR 1.97(b)**

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.


**37 CFR 1.97(c)**

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

☐ the statement specified in 37 CFR 1.97(e);

**OR**

☐ the fee set forth in 37 CFR 1.17(p).



## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket Number (Optional)

RGT 7033

Application Number

10/757,343

Applicant(s)

Liszewicz, et al.

Filing Date

14 Jan 2004

Group Art Unit

1633

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		6,420,176		Liszewicz and Lori			
		6,348,450					

## FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
							YES	NO
		WO 99/43350						
		PCT/US02/16546						

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)


EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>INFORMATION DISCLOSURE CITATION</b> <i>(Use several sheets if necessary)</i>		Docket Number (Optional) <b>RGT 7033</b>		Application Number <b>10/757,343</b>	
		Applicant(s) <b>Liszewicz, et al.</b>			
		Filing Date <b>14 Jan 2004</b>		Group Art Unit <b>1633</b>	
<b>*EXAMINER INITIAL</b>	<b>OTHER DOCUMENTS</b> <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>				
		Robinson, H. L. (2002). "New hope for an AIDS vaccine." Nature Rev Immunol 2(4): 239-50.			
		Fields, B. N. and D. M. Knipe, Eds. (1990). Virology. Retroviridae and their replication. New York, Raven Press, LTD			
		Chen, S. S., A. A. Ferrante, et al. (1996). "Characterization of an envelope mutant of HIV-1 that interferes with viral infectivity." Virology 226(2): 260-8			
		Smythe, J. A., D. Sun, et al. (1994). "A Rev-inducible mutant gag gene stably transferred into T lymphocytes: an approach to gene therapy against human immunodeficiency virus type 1 infection." Proc Natl Acad Sci U S A 91(9): 3657-61			
		Yung, E., M. Sorin, et al. (2001). "Inhibition of HIV-1 virion production by a transdominant mutant of integrase interactor 1." Nat Med 7(8): 920-6			
		Plavec, I., M. Agarwal, et al. (1997). "High transdominant RevM10 protein levels are required to inhibit HIV-1 replication in cell lines and primary T cells: implication for gene therapy of AIDS." Gene Ther 4(2): 128-39			
		Fraisier, C., D. A. Abraham, et al. (1998). "Inhibition of Tat-mediated transactivation and HIV replication with Tat mutant and repressor domain fusion proteins." Gene Ther 5(7): 946-54			
		Sawaya, B. E., K. Khalili, et al. (2000). "Transdominant activity of human immunodeficiency virus type 1 Vpr with a mutation at residue R73." J Virol 74(10): 4877-81			
		Gitlin, S. D., P. F. Lindholm, et al. (1991). "Transdominant human T-cell lymphotropic virus type I TAX1 mutant that fails to localize to the nucleus." J Virol 65(5): 2612-21			
		Bohnlein, S., F. P. Pirker, et al. (1991). "Transdominant repressors for human T-cell leukemia virus type I rex and human immunodeficiency virus type 1 rev function." J Virol 65(1): 81-8			
		Smith, C. A. and N. A. DeLuca (1992). "Transdominant inhibition of herpes simplex virus growth in transgenic mice." Virology 191(2): 581-8			
		Chen, J., C. Panagiotidis, et al. (1992). "Multimerization of ICP0, a herpes simplex virus immediate-early protein." J Virol 66(9): 5598-602			
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>			
<b>*EXAMINER:</b> Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					



<b>INFORMATION DISCLOSURE CITATION</b> <i>(Use several sheets if necessary)</i>		Docket Number (Optional)	Application Number
		RGT 7033	10/757,343
		Applicant(s)	
		Liszewicz, et al.	
		Filing Date	Group Art Unit
		14 Jan 2004	1633

*EXAMINER INITIAL	OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>
	Piccinini, G., A. Foli, et al. (2002). "Complementary antiviral efficacy of hydroxyurea and protease inhibitors in human immunodeficiency virus-infected dendritic cells and lymphocytes." J Virol 76(5): 2274-8
	Jayan, G. C., P. Cordelier, et al. (2001). "SV40-derived vectors provide effective transgene expression and inhibition of HIV-1 using constitutive, conditional, and pol III promoters." Gene Ther 8(13): 1033-42
	Frankel, S. S., K. Tenner-Racz, et al. (1997). "Active replication of HIV-1 at the lymphoepithelial surface of the tonsil." Am J Pathol 151(1): 89-96
	Jamieson, B. D., G. M. Aldrovandi, et al. (1994). "Requirement of human immunodeficiency virus type 1 nef for in vivo replication and pathogenicity." J Virol 68(6): 3478-85
	Aldrovandi, G. M., L. Gao, et al. (1998). "Regions of human immunodeficiency virus type 1 nef required for function in vivo." J Virol 72(9): 7032-9
	Geffin, R., D. Wolf, et al. (2000). "Functional and structural defects in HIV type 1 nef genes derived from pediatric long-term survivors." AIDS Res Hum Retroviruses 16(17): 1855-68
	Liszewicz, J., D. I. Gabrilovich, et al. (2001). "Induction of potent human immunodeficiency virus type 1-specific T-cell-restricted immunity by genetically modified dendritic cells." J Virol 75(16): 7621-8
	Zufferey, R., T. Dull, et al. (1998). "Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery." J Virol 72(12): 9873-80
	Vicenzi, E., D. S. Dimitrov, et al. (1994). "An integration-defective U5 deletion mutant of human immunodeficiency virus type 1 reverts by eliminating additional long terminal repeat sequences." J Virol 68(12): 7879-90
	Zhou, H., G. J. Rainey, et al. (2001). "Substrate sequence selection by retroviral integrase." J Virol 75(3): 1359-70
	Murphy, J. E. and S. P. Goff (1989) "Construction and analysis of deletion mutations in the U5 region of Moloney murine leukemia virus: effects on RNA packaging and reverse transcription." J Virol 63(1): 319-27
	Liszewicz, J., E. Rosenberg, et al. (1999). "Control of HIV despite the discontinuation of antiretroviral therapy." N Engl J Med 340(21): 1683-4

EXAMINER	DATE CONSIDERED
----------	-----------------

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>INFORMATION DISCLOSURE CITATION</b> <i>(Use several sheets if necessary)</i>		Docket Number (Optional) <b>RGT 7033</b>	Application Number <b>10/757,343</b>
		Applicant(s) <b>Liszewicz, et al.</b>	
		Filing Date <b>14 Jan 2004</b>	Group Art Unit <b>1633</b>
•EXAMINER INITIAL	OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>		
	Lori, F., M. G. Lewis, et al. (2000). "Control of SIV rebound through structured treatment interruptions during early infection." Science 290(5496): 1591-3		
	Rosenberg, E. S., M. Altfeld, et al. (2000). "Immune control of HIV-1 after early treatment of acute infection." Nature 407(6803): 523-6		
	Barouch, D. H., J. Kunstman, et al. (2002). "Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes." Nature 415(6869): 335-9		
	Trono, D., M. B. Feinberg, et al. (1989). "HIV-1 gag mutants can dominantly interfere with the replication of the wild-type virus." Cell 59: 113-120		
	Grant, E. P., M. T. Michalek, et al. (1995). "Rate of antigen degradation by the ubiquitin-proteasome pathway influences MHC class I presentation." J Immunol 155(8): 3750-8		
EXAMINER		DATE CONSIDERED	
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			